Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.61 |
| ▸ | PPARA | Q07869 | 14/20 | 0.61 |
| ▸ | PPARD | Q03181 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3279757 | 0.90 | PPARG (0.63) | PPARGPPARAPPARD | |
| SCHEMBL3278877 | 0.88 | PPARG (0.61) | PPARGPPARAPPARD | |
| SCHEMBL3279195 | 0.83 | FFAR1 (0.63) | PPARGPPARA | |
| SCHEMBL3294450 | 0.83 | PPARG (0.59) | PPARGPPARAPPARD | |
| SCHEMBL3280321 | 0.83 | PPARG (0.66) | PPARGPPARAPPARD | |
| SCHEMBL3284439 | 0.83 | PPARG (0.61) | PPARGPPARAPPARD | |
| SCHEMBL3281016 | 0.83 | PPARG (0.59) | PPARGPPARAPPARD | |
| SCHEMBL3294447 | 0.82 | PPARG (0.60) | PPARGPPARAPPARD | |
| SCHEMBL3287545 | 0.81 | PPARG (0.64) | PPARGPPARAPPARD | |
| SCHEMBL4029543 | 0.81 | PPARG (0.67) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700637-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | NOVARTIS AG (CH) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | PPARG, GPR119, PPARA | PPARG 1/4885PPARA 3/4885PPARD 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.